Scientific innovation only reaches its full potential when it translates into meaningful impact for patients. Pharming, a global biotechnology company that develops and commercializes innovative medicines for people living with rare immune and genetic diseases, has established a strong commercial foundation and deep rare disease expertise through RUCONEST. 

Building on that foundation, the growth and progress achieved with Joenja are helping drive Pharming’s evolution into a broader global rare disease company. Using the Joenja journey, including expansion into pediatric populations and the company’s growing geographic footprint across the US and international markets, this presentation will showcase that evolution, highlight Pharming’s advancing rare disease pipeline, and explore how science, clinical development and commercial execution can come together to turn innovation into patient impact.

.